Regenxbio Seeks FDA Approval for Duchenne Muscular Dystrophy Gene Therapy

Regenxbio is set to apply for accelerated approval from the FDA for its gene therapy treatment targeting Duchenne muscular dystrophy. The move could bring a significant breakthrough in treating this debilitating condition.